AndhraNews.net
Home » Business News » 2012 » April » April 2, 2012

Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe


April 2, 2012 - Tokyo

Eisai Co., Ltd. and Minophagen Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).

Under the terms of the agreement, Eisai shall grant Minophagen Pharmaceutical the exclusive rights to develop and commercialize bexarotene in Asia, Oceania, the Middle East and Eastern Europe, amongst other regions. However, Eisai retains the right of first negotiation for the commercialization of the agent in the licensed territories, if and when it is approved. In addition, Eisai will receive from Minophagen Pharmaceutical a one-time lump sum payment upon conclusion of the agreement as well as milestone payments and royalties on future sales.

Bexarotene was granted orphan drug status in the United States in 1999, and is currently approved and marketed as a treatment for recurrent and refractory CTCL in over 20 countries worldwide including the United States and those in Europe. Eisai obtained the exclusive worldwide rights to bexarotene when it acquired the agent from U.S.-based Ligand Pharmaceuticals Inc. in October 2006. Bexarotene is currently marketed in the United States by Eisai's U.S. subsidiary Eisai Inc. under the brand name Targretin. The exclusive rights to develop and commercialize the agent in Japan were granted to Minophagen Pharmaceutical by Eisai in March 2011.

CTCL is a type of cutaneous lymphoma that is characterized by the proliferation of T-cells in the skin. This type of lymphoma may reoccur in the same spot or spread to other parts of the body, progressing slowly over anywhere between a few years to a few decades, and is rarely associated with poor prognosis. Mycosis fungoides and Sezary syndrome are known as the two most common forms of CTCL. An extremely rare disease, CTCL affects between 16,000 and 20,000 patients in the United States, with approximately 1,500 new cases being diagnosed each year1). Bexarotene is recommended as a treatment for CTCL in NCCN (National Comprehensive Cancer Network) and other major treatment guidelines in the United States and Europe.

With the conclusion of the agreement, Eisai and Minophagen Pharmaceutical will work closely together to provide bexarotene as a new treatment option as early as possible in order to help address the unmet medical needs of CTCL patients in Japan, Asia, Oceania, the Middle East and Eastern Europe, amongst other regions.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html



Source: Eisai

Contact:

Public Relations Department
Eisai Co. Ltd
+81-(0)3-3817-5120



Copyright 2011 JCN Newswire. All rights reserved. www.japancorp.net

ACN Newswire

Comment on this story

Share